Neuroscience
 
Video - New insights into brain neuroplasticity
  
 
video
 High Bandwidth
line
WPA Bulletin
  
   
   
line
How to get published
  
 
more details...  
line
 
 
 
 Psylink (in french)
  
line
 
Dialogues in
Clinical Neurosciences
  
 
A quarterly publication, created in 1998, and since January 2003 it has been indexed in the international databases EMBASE and BIOBASE.
  
  bullet http://www.dialogues-cns.org  
 
 
 

STABLON : a first-line antidepressant

Indication

Depression is a serious and common illness, which can run a chronic course and is associated with both frequent morbidity and high mortality.

According to various reports, depression is one of the five leading causes of handicap in the World today.

STABLON is an antidepressant that has proven its value in the first-line treatment of depression, due to its efficacy and excellent acceptability profile.

From a clinical point of view, Stablon has demonstrated its superiority to placebo in several double-blind studies.1,2
In addition, the efficacy of Stablon versus both tricyclics and SSRIs has been demonstrated in several studies1,3,4 including a meta-analysis versus SSRIs that demonstrated that Stablon was at least as effective as SSRIs.5

In addition to its efficacy, Stablon's acceptability profile explains why it preserves patients' quality of life so well.3
Indeed, Stablon's adverse events are generally mild to moderate, and very infrequent.
Also, Stablon does not induce the sexual disturbances so frequently seen with other antidepressants.
In placebo-controlled studies1,2 the adverse event profile of Stablon was similar to that of placebo.

In recent studies versus SSRIs, Stablon confirmed its safety profile to be as good as those of SSRIs and in some cases better.6,7

Another key advantage of Stablon is its ability to relieve anxious symptoms in depressed patients, leading to a dramatic and significant decrease of anxiolytic coprescription compared with other antidepressants.8
Stablon differs from other antidepressants in its property of modulating the serotonin-mediated system and its protective effect against the deleterious effects of the stress-induced activation of the HPA axis.9 A new in vivo study confirms that Stablon reverses the impairment of brain structural plasticity induced by depression: brain metabolites, hippocampal volume and cell proliferation.10

Finally, Stablon can be easily prescribed, right from the start, at the effective dosage of one tablet tid, ie, 37.5 mg per day of tianeptine.
 
Attached References
 
  1. Cassano GB, Heinze G, Lôo H, et al. A double-blind comparison of tianeptine, imipramine and placebo in the treatment of major depressive episodes. Eur Psychiatry. 1996;11:254-259.

  2. Costa e Silva JA, Ruschel SI, Caetano D, et al. Placebo-controlled study of tianeptine in major depressive episodes. Neuropsychobiology. 1997;35:24-29.

  3. Wagstaff AJ, Ormrod D, Spencer CM. Tianeptine: a review of its use in depressive disorders CNS Drugs. 2001;15:231-259

  4. Lôo H, Saiz-Ruiz J, Costa e Silva JA, Ansseau M, et al. Efficacy and safety of tianeptine in the treatment of depressive disorders in comparison with fluoxetine. J Affect Dis. 1999;56:109-118.

  5. Olié JP, Poirier MF. A meta-analysis of tianeptine versus SSRIs in the treatment of depression. Poster presented at: World Congress of Biological Psychiatry; 1-6 July, 2001; Berlin.

  6. Lepine JP, Altamura C, Ansseau M, et al. Tianeptine and paroxetine in major depressive disorder, with a special focus on the anxious component in depression: an international, 6-week double-blind study. Hum Psychopharmacol. 2001;16:219-227.

  7. Faltus F, Novotny V, Raboch J, Zucha I. Tianeptine for the treatment of major depressive episode: a double-blind study versus fluoxetine. European Psychiatry. oct 2000;15(suppl 2):419s.

  8. Alby JM, Ferreri M, Cabane J, de Bodinat C, Dagens V. Efficacy of tianeptine in the treatment of major depression and dysthymia, with somatic complaints. Ann Psychiatry. 1993;8:136-144.

  9. Magariños AM, Deslandes A, McEwen BS. Antidepressant modulation and benzodiazepine treatments on the dendritic structure of CA3 pyramidal neurons after chronic stress. Eur J Pharmacol. 1999 Apr 29;371:113-122.

  10. Czéh B, Michaelis T, Watanabe T, Frahm J, de Biurrun G, Van Kampen M, Bartolomucci A, and Fuchs E. Stress-induced changes in cerebral metabolites, hippocampal volume, and cell proliferation are prevented by antidepressant treatment with tianeptine. Proc Natl Acad Sci U S A. 2001. In press.
top
   
© 2002 - 2003 SERDIA PHARMACEUTICALS (INDIA) PVT. LTD. -  All Rights Reserved - Terms of Use
SERDIA does not sell its products over the Internet - More information
Site developed and maintained by E Vision Technologies